Andreas Grainacher, a transfusion medicine expert at the University of Greifswald, announced the collaboration after the European Medicines Agency (EMA) said it would add a poster to the Johnson & Johnson vaccine warning of unusual blood clots with low platelet counts. AstraZeneca has a similar warning.
As with AstraZeneca, the European Medicines Agency said the benefits of getting a dose of the Johnson & Johnson vaccine still outweighed the risk of thrombosis, a position that Grainacher also supports.
And Greenscher released Tuesday. New paper Provides a possible explanation for the complications, and expressed his wish to obtain samples of the Johnson & Johnson vaccine for study in his laboratory.
“We agreed today with Johnson & Johnson that we will work together,” said Grainacher, in a press conference. “What I need most, which I expressed to the company, is that I would like to have the vaccine, because the Johnson & Johnson vaccine is not available in Germany.
Johnson & Johnson did not immediately respond to a Reuters request for comment.
Since mid-March, Grainacher’s team has been analyzing samples from people who have had clots after receiving an injection of AstraZeneca.
Grainacher’s paper examines the possibility of the body producing an immune response to some vaccines by activating factors that cause the growth of platelets in the bodies of recipients of some vaccines, which may cause clots.
In his paper, Grainacher examines the possibility of an immune response against vaccines similar to the “heparin drug-induced immune thrombocytopenia” disorder, and that the body may respond to some Covid-19 vaccines in the opposite way.
For its part, the European Medicines Agency said it suspects the vaccine may cause an unwanted immune response, but Sabine Strauss, head of the safety committee, said that she has not yet identified specific risk factors.
“It would be very helpful to know in advance if the cause was some kind of genetic disorder or something else in the blood vessels,” Strauss told reporters.
But Grainacher does not think such a possibility, based on his experiences with the heparin-induced immune thrombocytopenia disorder, which challenges efforts to determine why some people are at risk of developing the condition.
He said, “We have performed an analysis of the complete genetic sequence of 3000 of these patients, and we have not been able to find a genetic predisposition” to the disease.
In his recent paper, which has not yet been reviewed by independent scientists, he suggested that the technology behind the “AstraZeneca” dose, some of its components and the strong immune response that stimulates it, may contribute to a chain of events that may outweigh many of the mechanisms that usually maintain a healthy diet. Human immunity is under control.
Health lawmakers and scientists are looking into whether the clotting problem might affect the entire class of so-called “viral vector vaccines”, and the European Medicines Agency indicates that this is possible while noting differences in the two vaccines.
The AstraZeneca and Johnson & Johnson vaccines use a common, albeit different, common cold virus to transmit instructions to cells to produce an immune response. The Johnson & Johnson vaccine uses a human adenovirus, while AstraZeneca uses an adenovirus from chimpanzees.
“Individuals are different, and only if nine or 10 vulnerabilities come together by chance, then we have a (problem),” said Grincher. “Otherwise, our built-in security systems prevent it and keep us safe.”